Aadi Bioscience (AADI)
(Real Time Quote from BATS)
$1.47 USD
+0.02 (1.38%)
Updated Aug 16, 2024 02:46 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AADI 1.47 +0.02(1.38%)
Will AADI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AADI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AADI
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
AADI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
Other News for AADI
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
Aadi Bioscience, Inc. 2024 Q2 - Results - Earnings Call Presentation
Aadi Bioscience Inc (AADI) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth and ...
TD Cowen Reaffirms Their Buy Rating on Aadi Bioscience (AADI)
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update